Ornithine Transcarbamylase (OTC) Deficiency Treatment Market, by Drug Type (Buphenyl, Ravicti, Ammonul, and Others), by Route of Administration (Oral and Intravenous), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Published In : Jan 2023

Code : CMI5514

Pages :457

Formats :

Excel and PDF

Industry : Pharmaceutical

Ornithine Transcarbamylase (OTC) Deficiency Treatment MarketSize and Trends

Global Ornithine Transcarbamylase (OTC) deficiency treatment market is estimated to be valued at US$ 810.4 million in 2023 and is expected to exhibit a CAGR of 4.25% during the forecast period (2023-2030). Increasing research and development activities for Ornithine Transcarbamylase (OTC) deficiency treatment by market players is expected to boost growth of the market over the forecast period. Moreover, increasing product approvals for Ornithine Transcarbamylase (OTC) deficiency treatment by regulatory bodies is expected to propel growth of the global Ornithine Transcarbamylase (OTC) deficiency treatment market over the forecast period

Global Ornithine Transcarbamylase (OTC) deficiency treatment market is segmented into Drug Type, Route of Administration, and Distribution Channel

Based on Drug Type, the market is segmented Buphenyl, Ravicti, Ammonul, and Others. Due to increased efficacy, drug cost, and improved patient compliance, Ravicti segment accounted for a significant share 35.2% in the global market in 2022.

In terms of Route of Administration, the global Ornithine Transcarbamylase (OTC) deficiency treatment market has been segmented into oral and intravenous.Market- Trends

On the basis of Distribution Channel, market has been divided into hospital pharmacies, retail pharmacies, and online pharmacies. Due to the higher number of prescriptions filled at thehospital pharmacies, favorable reimbursement scenario, strong supply chain management, and various patient assistance programme run by pharmaceutical companies, the hospital pharmacies segment expected to dominate the market over forecast period.